Age-related differences in the β-adrenergic vasodilator response in rat aortic rings

Proceedings of the Western Pharmacology Society

Volumn 53, Issue , 2010, Pages 29-32

  Castillo Hernandez, Maria Del Carmen ^a   Meraz Cruz, Noemi ^b   Guevara Balcazar, Gustavo ^a   Lopez Canales, Jorge ^a,b   Lopez Canales, Oscar ^a   Galindo, Norma ^b   Castillo Henkel, Carlos ^a,b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; TETRYLAMMONIUM;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM; GROUPS BY AGE; INHIBITION KINETICS; MALE; NONHUMAN; RAT; VASCULAR RING; WISTAR RAT; AGE; ANIMAL; AORTA; DRUG EFFECT; IN VITRO STUDY; PHYSIOLOGY; VASODILATATION;

AGE FACTORS; ANIMALS; AORTA; ISOPROTERENOL; MALE; NG-NITROARGININE METHYL ESTER; POTASSIUM CHLORIDE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; TETRAETHYLAMMONIUM COMPOUNDS; VASODILATION;

EID: 84555218613     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bisset-Valiente D, Alfonso Z.C, Bernardo-Fuentes M, Molina-García J.R and González-Cabrales VT. Rev Cubana Invest Biomed 1999; 18(2): 104-110.
2. Baker H. J., Russel-Lindsey J. y Weisbroth S. H. (1979). The laboratory rat Volumen 1 Biology and diseases. Editorial Academic Press. New York, USA.
3. Schutzer W.E. and Mader S.L. Age-related changes in vascular adrenergic signaling: clinical and mechanistic implications. Ageing Res Rev. 2003; 2(2): 169-90. (Pubitemid 37443911)
4. Tsujimoto G, Hashimoto K. y Hoffman B. B. (1987). Am J Physiol Heart Circ Physiol. 1987; 252: H513-H520.
5. Paul RJ., Bowman P.S., Johnson J. and Martin A.F. (2007). Am J Physiol Regulatory Integrative Comp Physiol. 2007; 292: R751 - R757
6. Elliott S. R. y Pearce W. J. (1994). Effects of maturation on alpha-adrenergic receptor affinity and occupancy in small cerebral arteries. Am J Physiol Heart Circ Physiol 267: H757-H763.
7. Tsujimoto G, Lee Chi-Ho y Hoffman BB. J Pharmacol Exp Ther. 1986; 239: 411-415.
8. Baloglu E, Kizitepe O and Gürdal H. Eur J Pharmacol.; 2007; 564: 167-173.
9. Van der Zypp A., Kang KB.and Majewski H. Eur. J. Pharmacol. 2000; 397: 129-138.
10. Borkowski KR, Gross R and Schneider H J Auton Pharmacol 1992; 12:389-401.
11. Chapman J, Schutzer W, Watts VJ and Mader SL. J Gerontol 1999;54:B154-B159.
12. Monopoli A., Conti A., Forlani A. and Ongini E. Pharmacol Res. 1993; 27:273-279.
13. Sun D, Huang A, Mital S, Kichuk M.R., Marboe C.C., Addonizio L.J., Michler R.E., Koller A., Hintze T.H. and Kaley G. Circulation 2002; 106: 550-555.
14. Trochu JN, Leblais V, Rautureau Y, Beverelli F, Le Marec H, Berdeaux A and Gauthier C. Br J Pharmacol 1999; 128: 69-76.
15. Rautureau Y, Toumaniantz G, Serpillon S, et al. Br J Pharmacol.2002; 137: 153-161.
16. Brawley L, Shaw AM, y MacDonald A. Eur J Pharmacol 2000; 398: 285-296.
17. Van der Zypp A., Kang KB. y Majewski H. Eur. J. Pharmacol. 2000; 397: 129-138.
18. Dessy C., Moniotte S., Ghisdal P., Havaux X., Noirhomme P., Balligand J.L., Circulation; 2004; 110: 948-954.